Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT OTCMKTS:CYAN NYSE:MRK NASDAQ:REVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$2.96+3.0%$3.09$2.56▼$7.73$574.66M0.214.26 million shs1.30 million shsCYANCyanotech$0.44$0.39$0.21▼$0.57$3.25M0.15671 shsN/AMRKMerck & Co., Inc.$119.29+4.0%$116.44$76.66▼$125.14$294.63B0.2110.77 million shs3.88 million shsREVBRevelation Biosciences$1.03-1.0%$1.12$0.88▼$12.88$4.03M-0.09409,934 shs18,253 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-1.21%-3.86%+1.60%-18.38%-47.14%CYANCyanotech0.00%-15.37%+13.08%+2.33%+8.00%MRKMerck & Co., Inc.-0.84%-4.44%+2.34%-0.94%+49.12%REVBRevelation Biosciences-1.89%-4.59%-7.14%-16.13%-90.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$2.96+3.0%$3.09$2.56▼$7.73$574.66M0.214.26 million shs1.30 million shsCYANCyanotech$0.44$0.39$0.21▼$0.57$3.25M0.15671 shsN/AMRKMerck & Co., Inc.$119.29+4.0%$116.44$76.66▼$125.14$294.63B0.2110.77 million shs3.88 million shsREVBRevelation Biosciences$1.03-1.0%$1.12$0.88▼$12.88$4.03M-0.09409,934 shs18,253 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-1.21%-3.86%+1.60%-18.38%-47.14%CYANCyanotech0.00%-15.37%+13.08%+2.33%+8.00%MRKMerck & Co., Inc.-0.84%-4.44%+2.34%-0.94%+49.12%REVBRevelation Biosciences-1.89%-4.59%-7.14%-16.13%-90.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.50Moderate Buy$16.67481.73% UpsideCYANCyanotech 0.00N/AN/AN/AMRKMerck & Co., Inc. 2.68Moderate Buy$128.1811.53% UpsideREVBRevelation Biosciences 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ALT, MRK, REVB, and CYAN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026REVBRevelation Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)6/2/2026ALTAltimmune CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/18/2026ALTAltimmune HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00 ➝ $20.005/15/2026MRKMerck & Co., Inc. Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/14/2026ALTAltimmune Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$14.00 ➝ $11.005/13/2026REVBRevelation Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)5/6/2026MRKMerck & Co., Inc. CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$125.005/1/2026MRKMerck & Co., Inc. Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)5/1/2026MRKMerck & Co., Inc. Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$150.00 ➝ $145.004/27/2026REVBRevelation Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/13/2026MRKMerck & Co., Inc. UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$130.00 ➝ $145.00(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$40K13,928.91N/AN/A$1.99 per share1.44CYANCyanotech$24.22M0.13N/AN/A$1.23 per share0.36MRKMerck & Co., Inc.$65.01B4.37$11.36 per share10.12$21.22 per share5.42REVBRevelation BiosciencesN/AN/AN/AN/A$1.28 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.09M-$0.93N/AN/AN/A-214,860.98%-42.57%-35.57%8/11/2026 (Estimated)CYANCyanotech-$3.20M-$0.25N/AN/AN/A-7.03%-20.62%-7.52%N/AMRKMerck & Co., Inc.$18.25B$3.5532.3711.752.6013.59%27.55%10.73%8/4/2026 (Estimated)REVBRevelation Biosciences-$8.91M-$39.48N/AN/AN/AN/A-107.65%-87.98%8/7/2026 (Estimated)Latest ALT, MRK, REVB, and CYAN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ALTAltimmune-$0.25-$0.18+$0.07-$0.18$0.00 millionN/A5/7/2026Q1 2026REVBRevelation Biosciences-$1.15-$2.71-$1.56-$2.71N/AN/A4/30/2026Q1 2026MRKMerck & Co., Inc.-$1.47-$1.28+$0.19-$1.72$15.85 billion$16.29 billion3/5/2026Q4 2025ALTAltimmune-$0.25-$0.2719-$0.0219-$0.27$0.00 million$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ACYANCyanotechN/AN/AN/AN/AN/AMRKMerck & Co., Inc.$3.402.96%+5.75%95.77%14 YearsREVBRevelation BiosciencesN/AN/AN/AN/AN/ALatest ALT, MRK, REVB, and CYAN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/26/2026MRKMerck & Co., Inc.quarterly$0.852.84%6/15/20266/15/20267/8/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmune0.1229.5629.56CYANCyanotech0.121.000.30MRKMerck & Co., Inc.1.021.301.06REVBRevelation BiosciencesN/A10.0210.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%CYANCyanotech24.40%MRKMerck & Co., Inc.76.07%REVBRevelation Biosciences12.80%Insider OwnershipCompanyInsider OwnershipALTAltimmune1.60%CYANCyanotech34.40%MRKMerck & Co., Inc.0.17%REVBRevelation Biosciences4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune50194.47 million191.36 millionOptionableCYANCyanotech957.39 million4.85 millionNot OptionableMRKMerck & Co., Inc.75,0002.47 billion2.47 billionOptionableREVBRevelation Biosciences103.91 million3.72 millionNot OptionableALT, MRK, REVB, and CYAN HeadlinesRecent News About These CompaniesRevelation Biosciences Expands Acute Kidney Injury Advisory BoardJune 1 at 9:00 AM | accessnewswire.comARevelation Biosciences, Inc. Releases Corporate Update Letter to StockholdersMay 11, 2026 | accessnewswire.comAREVB Poised for Big YearMay 8, 2026 | finance.yahoo.comRevelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026May 7, 2026 | accessnewswire.comARevelation Biosciences Announces Formation of Acute Kidney Injury Advisory BoardApril 6, 2026 | accessnewswire.comARevelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical StudyMarch 30, 2026 | oklahoman.comORevelation Biosciences (REVB) price target decreased by 37.65% to 54.06March 28, 2026 | msn.comREMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth ConferenceMarch 24, 2026 | accessnewswire.comARevelation Biosciences to Host Fireside Chat at 38th Annual Roth ConferenceMarch 19, 2026 | accessnewswire.comARevelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025February 26, 2026 | accessnewswire.comARevelation Biosciences (REVB) price target increased by 300.00% to 86.70February 4, 2026 | msn.comREVB Comes to Agreement with FDAJanuary 29, 2026 | finance.yahoo.comREVB stock drops 10% after company announces third reverse split in a yearJanuary 26, 2026 | msn.comRevelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026January 26, 2026 | accessnewswire.comARevelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross ProceedsJanuary 23, 2026 | accessnewswire.comARevelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKIJanuary 21, 2026 | accessnewswire.comARevelation Biosciences, Inc.: Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care NephrologyJanuary 14, 2026 | finanznachrichten.deRevelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)January 14, 2026 | accessnewswire.comARevelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)January 12, 2026 | accessnewswire.comARevelation Biosciences, Inc.: Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical DevelopmentJanuary 8, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesIonQ Just Posted a Breakout Quarter—But 1 Problem RemainsBy Nathan Reiff | May 7, 2026What the FDA's Latest Proposal Means for Lilly, Novo, and HimsBy Leo Miller | May 7, 2026Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming DueBy Bridget Bennett | May 9, 2026Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in FocusBy Jessica Mitacek | May 8, 20263 Healthcare Stocks Set to Benefit From the One Big Beautiful BillBy Chris Markoch | May 10, 2026ALT, MRK, REVB, and CYAN Company DescriptionsAltimmune NASDAQ:ALT$2.96 +0.09 (+2.96%) As of 01:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Cyanotech OTCMKTS:CYAN$0.44 0.00 (0.00%) As of 06/2/2026Cyanotech Corp. engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company was founded by Gerald R. Cysewski in 1983 and is headquartered in Kailua-Kona, HI.Merck & Co., Inc. NYSE:MRK$119.27 +4.57 (+3.99%) As of 01:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.Revelation Biosciences NASDAQ:REVB$1.03 -0.01 (-0.96%) As of 12:52 PM Eastern This is a fair market value price provided by Massive. Learn more.Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker Ulta's Q1 Report Primes It for a Beauty of a Rebound Palo Alto Networks Accelerates Growth 31% on AI Demand How the Memory Shortage Is Crushing the Gaming Industry As AI Data Breaches Become More Common, This Cybersecurity ETF Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
